Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernd Krause is active.

Publication


Featured researches published by Bernd Krause.


International Journal of Radiation Oncology Biology Physics | 2009

Assessment of Tumor Volumes in Skull Base Glomus Tumors Using Gluc-Lys[

Sabrina T. Astner; Ralph Bundschuh; Ambros Beer; Sibylle Ziegler; Bernd Krause; Markus Schwaiger; Michael Molls; Anca L. Grosu; Markus Essler

PURPOSE To assess a threshold for Gluc-Lys[(18)F]-TOCA positron emission tomography (PET) in target volume delineation of glomus tumors in the skull base and to compare with MRI-based target volume delineation. METHODS AND MATERIALS The threshold for volume segmentation in the PET images was determined by a phantom study. Nine patients with a total of 11 glomus tumors underwent PET either with Gluc-Lys[(18)F]-TOCA or with (68)Ga-DOTATOC (in 1 case). All patients were additionally scanned by MRI. Positron emission tomography and MR images were transferred to a treatment-planning system; MR images were analyzed for lesion volume by two observers, and PET images were analyzed by a semiautomated thresholding algorithm. RESULTS Our phantom study revealed that 32% of the maximum standardized uptake value is an appropriate threshold for tumor segmentation in PET-based target volume delineation of gross tumors. Target volume delineation by MRI was characterized by high interobserver variability. In contrast, interobserver variability was minimal if fused PET/MRI images were used. The gross tumor volumes (GTVs) determined by PET (GTV-PET) showed a statistically significant correlation with the GTVs determined by MRI (GTV-MRI) in primary tumors; in recurrent tumors higher differences were found. The mean GTV-MRI was significantly higher than mean GTV-PET. The increase added by MRI to the common volume was due to scar tissue with strong signal enhancement on MRI. CONCLUSIONS In patients with glomus tumors, Gluc-Lys[(18)F]-TOCA PET helps to reduce interobserver variability if an appropriate threshold for tumor segmentation has been determined for institutional conditions. Especially in patients with recurrent tumors after surgery, Gluc-Lys[(18)F]-TOCA PET improves the accuracy of GTV delineation.


European Journal of Nuclear Medicine and Molecular Imaging | 2013

^18

Ralph Bundschuh; Christina Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; H. Kübler; Tobias Maurer; J.E. Gschwend; Hans Geinitz; Anca L. Grosu; Sibylle Ziegler; Bernd Krause


Molecular Imaging and Biology | 2011

F]-TOCA Positron Emission Tomography

Ken Herrmann; Ralph Bundschuh; Robert Rosenberg; Stefan Schmidt; Christine Praus; Michael Souvatzoglou; Karen Becker; Tibor Schuster; Markus Essler; Hinrich A. Wieder; Helmut Friess; Sibylle Ziegler; Markus Schwaiger; Bernd Krause


Nuklearmedizin | 2009

Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Michael Schäfers; Frank Bengel; U. Büll; Wolfgang Burchert; Peter Kies; Regine Kluge; Bernd Krause; Oliver Lindner; Christoph A. Nienaber; Bernd Nowak; W. Schäfer; Otmar Schober; Markus Schwaiger; Sigmund Silber; Jürgen vom Dahl; Rainer Zimmermann


Society of Nuclear Medicine Annual Meeting Abstracts | 2011

Comparison of Different SUV-Based Methods for Response Prediction to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer by FDG-PET and MRI

Niklaus Schaefer; Ray Valencia; Sandra Borkowski; Eva Geissler; Glen Kristiansen; Beate Rohde; Claudia Bacher-Stier; Bernd Krause; Thomas F. Hany


Society of Nuclear Medicine Annual Meeting Abstracts | 2011

Position paper nuclear cardiology: Update 2008 - State-of-the-art of scintigraphic methods

Kamilla Smolarz; Bernd Krause; Frank-Philipp Graner; Franziska Wagner; Claudia Bacher-Stier; Rick Sparks; Susan Ramsay; Luder Fels; Ludger Dinkelborg; Markus Schwaiger


Society of Nuclear Medicine Annual Meeting Abstracts | 2010

Comparison of BAY 86-4367, a new F-18 labeled bombesin analog, with F-18-ethyl-choline in recurrent and primary prostate cancer patients

Bernd Krause; Kamilla Smolarz; Hans-Jurgen Wester; Franziska Wagner; Benedetta Belloni; Christian Meyer zum Büschenfelde; Claudia Bacher-Stier; Luder Fels; Ludger Dinkelborg; Markus Schwaiger


Der Kardiologe | 2009

BAY 94-9392: A novel F-18 labeled tumor specific probe for PET/CT imaging - Dosimetry

Michael Schäfers; Frank M. Bengel; U. Büll; Wolfgang Burchert; Peter Kies; Regine Kluge; Bernd Krause; Oliver Lindner; Christoph Nienaber; Bernd Nowak; W. Schäfer; Otmar Schober; M. Schwaiger; Sigmund Silber; Lars Stegger; J. vom Dahl; Rainer Zimmermann


Society of Nuclear Medicine Annual Meeting Abstracts | 2009

[18F]BAY 85-8050 (TIM-1): A novel tumor specific probe for PET/CT imaging - First clinical results

Matthias Eiber; Bernd Krause; Juergen E. Gschwend; Markus Schwaiger; Ambros Beer


Society of Nuclear Medicine Annual Meeting Abstracts | 2006

Positionspapier Nuklearkardiologie@@@Position paper on nuclear cardiology by the German Cardiac Society: Aktueller Stand der klinischen Anwendung@@@State of the art of clinical application

Ken Herrmann; Tobias Dechow; Marion Schoeffel; Christian v. Schilling; Bernd Krause; Hans-Juergen Wester; Wolfgang Weber; Christian Peschel; Markus Schwaiger; Hinrich Wieder

Collaboration


Dive into the Bernd Krause's collaboration.

Top Co-Authors

Avatar

Markus Essler

University Hospital Bonn

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Luder Fels

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Matthias Eiber

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge